Astrazeneca UK Ltd. v. Aurobindo Pharma Ltd.
413 F. App'x 288
CourtCourt of Appeals for the Federal Circuit
DecidedMarch 24, 2011
DocketNos. 2010-1460, 2010-1461, 2010-1462, 2010-1463, 2010-1464, 2010-1465, 2010-1466, 2010-1467, 2010-1468, 2010-1469, 2010-1470, 2010-1471, 2010-1472, 2010-1473
StatusPublished
Cited by1 cases
This text of 413 F. App'x 288 (Astrazeneca UK Ltd. v. Aurobindo Pharma Ltd.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Astrazeneca UK Ltd. v. Aurobindo Pharma Ltd., 413 F. App'x 288 (Fed. Cir. 2011).
Opinion
MOTION
ORDER
Apotex Corp. moves for separate oral argument with respect to an issue in these appeals.
Upon consideration thereof,
It Is Ordered That:
The motion is deferred for consideration by the merits panel assigned to hear this case. Copies of this order, the motion and any response shall be transmitted to the merits panel.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
L'Oreal USA, Inc. v. Olaplex, Inc.
Federal Circuit, 2021
Cite This Page — Counsel Stack
Bluebook (online)
413 F. App'x 288, Counsel Stack Legal Research, https://law.counselstack.com/opinion/astrazeneca-uk-ltd-v-aurobindo-pharma-ltd-cafc-2011.